- Home
- RPRX vs MEDP Comparison
RPRX vs MEDP Comparison
Compare RPRX & MEDP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- RPRX
- MEDP
- Stock Information
- Founded
- RPRX 1996
- MEDP 1992
- Country
- RPRX United States
- MEDP United States
- Employees
- RPRX N/A
- MEDP N/A
- Industry
- RPRX Biotechnology: Pharmaceutical Preparations
- MEDP Biotechnology: Commercial Physical & Biological Resarch
- Sector
- RPRX Health Care
- MEDP Health Care
- Exchange
- RPRX Nasdaq
- MEDP Nasdaq
- Market Cap
- RPRX 15.6B
- MEDP 13.4B
- IPO Year
- RPRX 2020
- MEDP 2016
- Fundamental
- Price
- RPRX $37.03
- MEDP $526.84
- Analyst Decision
- RPRX Strong Buy
- MEDP Hold
- Analyst Count
- RPRX 4
- MEDP 11
- Target Price
- RPRX $44.50
- MEDP $428.10
- AVG Volume (30 Days)
- RPRX 3.5M
- MEDP 282.8K
- Earning Date
- RPRX 11-05-2025
- MEDP 10-22-2025
- Dividend Yield
- RPRX 2.38%
- MEDP N/A
- EPS Growth
- RPRX 54.86
- MEDP 26.42
- EPS
- RPRX 2.32
- MEDP 13.46
- Revenue
- RPRX $2,305,243,000.00
- MEDP $2,231,787,000.00
- Revenue This Year
- RPRX $35.14
- MEDP $19.06
- Revenue Next Year
- RPRX $1.24
- MEDP $8.64
- P/E Ratio
- RPRX $15.92
- MEDP $39.24
- Revenue Growth
- RPRX 3.02
- MEDP 9.94
- 52 Week Low
- RPRX $24.05
- MEDP $250.05
- 52 Week High
- RPRX $38.00
- MEDP $547.15
- Technical
- Relative Strength Index (RSI)
- RPRX 61.20
- MEDP 59.43
- Support Level
- RPRX $35.23
- MEDP $510.12
- Resistance Level
- RPRX $36.36
- MEDP $527.42
- Average True Range (ATR)
- RPRX 0.63
- MEDP 17.52
- MACD
- RPRX 0.11
- MEDP -2.58
- Stochastic Oscillator
- RPRX 95.38
- MEDP 61.66
About RPRX Royalty Pharma plc
Royalty Pharma PLC is the largest buyer of biopharmaceutical royalties. The firm has a portfolio of royalties that entitles it to payments based on the sales of biopharma products. Royalty Pharma receives royalties on more than 35 commercial products, including AbbVie and Johnson & Johnson's Imbruvica (for chronic lymphocytic leukemia and other blood cancers), Biogen's Tysabri (for relapsing forms of multiple sclerosis), Vertex's cystic fibrosis franchise, and 10 development-stage product candidates.
About MEDP Medpace Holdings Inc.
Medpace is a late-stage contract research organization that provides full-service drug-development and clinical trial services to small and midsize biotechnology, pharmaceutical, and medical device firms. It also offers ancillary services, including bioanalytical laboratory services and imaging capabilities. The company was founded over 30 years ago and has more than 5,400 employees across 40 countries. Medpace is headquartered in Cincinnati, Ohio, and its operations are primarily based in the US, with additional presence in Europe, Asia, South America, Africa, and Australia. Cinven, a global private equity firm, acquired Medpace for $915 million in 2014 and exited its investment in 2018.